ST. LOUIS, MISSOURI (RFD-TV) — Monsanto, a subsidiary of Bayer, announced a proposed nationwide U.S. class settlement designed to resolve current and future claims related to Roundup™ exposure and Non-Hodgkin lymphoma (NHL). The settlement, which requires court approval, would provide up to $7.25 billion in funding through declining capped annual payments over 21 years, giving Monsanto greater financial certainty.
The proposed class settlement complements ongoing U.S. Supreme Court review of the Durnell case, which addresses whether state failure-to-warn claims are preempted by federal law. Bayer described the class settlement and Supreme Court case as mutually reinforcing strategies to contain the multi-billion-dollar Roundup™ litigation.
“This settlement provides an essential path out of litigation uncertainty and allows us to focus on innovations that support our mission: Health for all, Hunger for none,” said Bayer COE Bill Anderson. Monsanto emphasized that the settlement does not constitute any admission of liability or wrongdoing.
In addition to this settlement, Monsanto has reached separate agreements on other Roundup™ and PCB-related cases, increasing Bayer’s total litigation provisions from €7.8 billion to €11.8 billion. The company expects a negative free cash flow for 2026 and has secured financing through an $8 billion bank facility.
The class settlement covers plaintiffs diagnosed with NHL prior to February 17, 2026, or diagnosed within 16 years after court approval, providing a long-term claims program managed by a professional administrator. Members of the class will receive notice and may opt out if desired.
